白细胞介素-17预测ST段抬高型心肌梗死患者经皮冠状动脉介入术后慢血流或无复流的价值  

Value of serum interleukin-17 in predicting slow flowor no reflow after percutaneous coronary interventionin patients with ST-elevation myocardial infarction

作　　者：林灵丹[1] 许士达 邢海燕[1] LIN Lingdan;XU Shida;XING Haiyan(Department of Cardiology,Dezhou City People′s Hospital,Dezhou,Shandong,253000)

机构地区：[1]山东省德州市人民医院心血管内科,山东德州253000

出　　处：《实用临床医药杂志》2021年第11期93-95,100,共4页Journal of Clinical Medicine in Practice

摘　　要：目的探讨血清白细胞介素-17(IL-17)水平预测ST段抬高型心肌梗死(STEMI)患者急诊经皮冠状动脉介入术(PCI)后慢血流或无复流的价值。方法将120例急诊行PCI的STEMI患者根据PCI后冠状动脉血流情况分为慢血流和无复流组27例,血流正常组93例。比较2组患者血清IL-17水平及临床资料,采用二元Logistic回归模型分析慢血流/无复流的影响因素,采用受试者工作特征(ROC)曲线分析慢血流/无复流的预测指标。结果慢血流和无复流组患者的IL-17、磷酸肌酸激酶同工酶(CK-MB)、肌钙蛋白I(cTnI)、C反应蛋白(CRP)水平均高于血流正常组,差异有统计学意义(P<0.05)。结论IL-17是慢血流/无复流的影响因素,血清IL-17水平升高与PCI后慢血流/无复流的发生有关,检测IL-17对PCI后慢血流或无复流具有预测价值。Objective To explore the value of serum interleukin-17(IL-17)level in predicting slow flow or no reflow after percutaneous coronary intervention(PCI)in patients with ST-elevation myocardial infarction(STEMI).Methods Totally 120 STEMI patients with emergency PCI were divided into slow flow and no reflow group(n=27)and normal flow group(n=93)according to coronary blood flow status after PCI.The serum IL-17 level and clinical data were compared between the two groups.The factors influencing slow flow or no reflow were analyzed by the binary Logistic regression model.The predictive indexes for slow flow or no reflow were analyzed by receiver operating characteristic(ROC)curve.Results The levels of IL-17,creatine kinase isoenzyme-MB(CK-MB),cardiac troponin I(cTnI)and C-reactive protein(CRP)in the slow flow and no reflow group were significantly higher than those in the normal flow group(P<0.05).Conclusion IL-17 was the influencing factor of slow flow or no reflow,the increase of serum IL-17 level is related to the occurrence of slow flow or no reflow after PCI,and the detection of IL-17 has a predictive value for slow flow or no reflow after PCI.

关 键 词：ST段抬高型心肌梗死 白细胞介素-17 慢血流 无复流 影响因素 预测价值 

分 类 号：R541.1[医药卫生—心血管疾病] R446.11[医药卫生—内科学]